Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Avipendekin pegol - Nektar Therapeutics

Drug Profile

Avipendekin pegol - Nektar Therapeutics

Alternative Names: NKTR-255; Polymer-conjugated IL-15 - Nektar Therapeutics

Latest Information Update: 13 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nektar Therapeutics
  • Developer AbelZeta Pharma; Fred Hutchinson Cancer Research Center; Gilead Sciences; Janssen; M. D. Anderson Cancer Center; Merck KGaA; Nektar Therapeutics; Stanford University
  • Class Antineoplastics; Antivirals; Immunotherapies; Interleukins; Recombinant fusion proteins
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Interleukin-15 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II/III B-cell lymphoma; Diffuse large B cell lymphoma
  • Phase II Non-small cell lung cancer; Urogenital cancer
  • Phase I/II Cervical cancer; Colorectal cancer; Squamous cell cancer
  • Phase I Multiple myeloma; Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
  • Preclinical Burkitt's lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; Triple negative breast cancer
  • Research Viral infections

Most Recent Events

  • 11 Dec 2023 Pharmacodynamics data from a preclinical trial in Burkitt's lymphoma released by Nektar Therapeutics
  • 09 Dec 2023 Updated pharmacodynamics data from a preclinical studies in Burkitt Lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-2023)
  • 20 Nov 2023 Cellular Biomedicine Group is now called AbelZeta Pharma
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top